Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M681Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M-8.5EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)17.4Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book1.510-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %4.0PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M47,300,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with PID

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

PID is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


PID: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Keogh, WillemSenior Officer 2016-09-08Buy338$21.28-32.42view
Sardo, Vincent JamesDirector 2016-09-08Sell1,500$43.05-66.6view
Larson, Douglas RobertDirector, Senior Officer 2016-09-08Sell800$8.3572.22view
Fraser, AlisonDirector or Senior Officer of Insider or Subsidiar 2016-09-08Sell12,700$10.1841.26view
Brown, ArthurDirector 2016-09-08Sell250,000$0.0720442.86view
Brewster, NormanSenior Officer 2016-09-08Sell45,000$0.0347833.33view
Darling, Neil B.T.Director 2016-09-08Buy53,500$0.275225.93view
Porter, Brian JDirector, Senior Officer 2016-09-08Sell25,176$70.17-79.51view
Marsh, John M.Director 2016-09-08Sell36,000$29.5-51.25view
Graham, Eric JohnSenior Officer 2016-09-08Buy1,700$3.23345.2view

Quarterly/Annual Reports about PID:

    News about PID:

    Articles On GuruFocus.com
    Searching The World For The Best Dividend Stocks Jan 06 2015 

    More From Other Websites
    Winning? We Review How Teva Dominates Generic Drug Space Sep 26 2016
    Sanofi’s Chase for Zika Virus Vaccine Could Drive Its Share Price Sep 15 2016
    Will Sanofi See More Growth from Its Blockbuster Insulin Drug? Sep 15 2016
    GSK Optimistic about Future of Its Consumer Healthcare Segment Sep 13 2016
    GlaxoSmithKline Giving a Shot to Its Vaccines Business Sep 13 2016
    GlaxoSmithKline’s Combo Treatment for HIV Faces Stiff Competition Sep 12 2016
    5 Undervalued ETFs for Dividend Lovers Sep 08 2016
    Analyzing Sanofi’s Asset Swap Deal with Boehringer Ingelheim Sep 08 2016
    Teva Pharmaceutical: A Successful Bond Financing Program in 2016 Aug 22 2016
    How Merial Contributes to Sanofi’s Growth Aug 22 2016
    What Happened to Sanofi’s Consumer Healthcare and Generics Franchise in 2Q16? Aug 19 2016
    Behind Sanofi’s Diabetes and Cardiovascular Performance in 2Q16 Aug 18 2016
    Genzyme Continued to Boost Growth for Sanofi in 2Q16 Aug 18 2016
    Inside Sanofi’s Valuation Changes Aug 17 2016
    How Did Novo Nordisk Perform across Geographies in 1H16? Aug 09 2016
    A New Low Volatile International ETF for Dividend Lovers Aug 08 2016
    A New Low Volatility International ETF for Dividend Lovers Aug 08 2016
    An Update on Shire’s Upcoming Milestones Aug 05 2016
    How Did GlaxoSmithKline’s Pharmaceuticals Segment Do in 2Q16? Aug 02 2016
    How Much Growth Will Novo See in 2Q16? Aug 01 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)